Photobiomodulation Effects on Blood Pressure and Vascular Function in Treated Hypertensive Patients
Recruiting · NCT07525310 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Sham PhotobiomodulationVascular Photobiomodulation
What this trial is about
This double-blind, randomized, sham-controlled clinical trial aims to evaluate the effects of vascular photobiomodulation on blood pressure and vascular function in hypertensive patients treated with losartan. A total of 80 patients using losartan (100 mg/day for at least two months) will be recruited and followed for 4 weeks. Participants will be randomly allocated to either an active photobiomodulation group or a sham control group.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Be taking losartan at a dose of 100 mg/day, either as monotherapy or in combination with other antihypertensive medications, administered in two divided doses, for a minimum of 2 months and a maximum of 24 months.
- Present systolic blood pressure is less than or equal to 140 mmHg and diastolic less than or equal to 90 mmHg.
- Not having used any other antihypertensive medication in the last 2 months.
- Age between 18 and 65 years
- If female, not pregnant
- No cutaneous/subcutaneous lesions on both arms.
- No musculoskeletal, rheumatic, cardiovascular, metabolic, neurological, oncological, immunological, hematological, psychiatric or cognitive diagnoses and that may be worsened by the intervention or prevent the correct application of FBM vascular.
Exclusion criteria
- Changes in medication status during the study
Where it is running
1 location listed.
- Raphael Dias - São Paulo, São Paulo, Brazil